Business
SOHM, Inc. Agrees to Licensing for Investigational and Pre-Clinical Studies for Groundbreaking ABBIE Genome Editing Technology for CAR-T Cell Cancer Therapies
SOHM, Inc. Agrees to Licensing for Investigational and Pre-Clinical Studies for Groundbreaking ABBIE Genome Editing Technology for CAR-T Cell Cancer Therapies.
About this update from Sohm, Inc.
[{"type":"text","content":"\r\n\r\n \r\n \r\n SOHM, Inc. Agrees to Licensing for Investigational and Pre-Clinical Studies for Groundbreaking ABBIE Genome Editing Technology for CAR-T Cell Cancer Therapies\r\n \r\n \r\n\r\n\r\nSOHM, Inc. Agrees to Licensing for Investigational and Pre-Clinical Studies for Groundbreaking ABBIE Genome Editing Technology for CAR-T Cell Cancer Therapies\r\n\r\n\r\n\r\n\r\n\r\nCHINO HILLS, CA / ACCESS Newswire / April 28, 2025 / SOHM, Inc. (OTC PINK:SHMN), a leading pharmaceutical and biotechnology company specializing in generic drugs and gene-editing tools, proudly announces today its collaboration and licensing agreement with an undisclosed emerging drug development partner. This partnership accentuates SOHM's leadership in gene editing and cell engineering.\r\n David Aguilar, PhD, Chief Operating Officer, stated that this collaborative and licensing project will position SOHM and its partners as leaders in microfluidic-based gene editing technology to develop new micro-dosed CAR-T cell therapies to treat cancers. As part of this alliance, our partners are licensing SOHM's proprietary genome editing ABBIE products and methods. This partnership marks a significant leap forward in developing novel genome editing technologies and CAR-T-based therapies poised to revolutionize treatments for cancer and other diseases.\r\n SOHM, Inc., is set to receive $6 million upon funding approval by its partners to advance their joint research initiative focused on developing cutting-edge genome editing products. For this initiative, SOHM's groundbreaking ABBIE (A Binding-based Integrase Enzyme) integration system is licensed to enhance autologous CAR-T cells' safe and efficient production, making significant strides toward clinical applications.\r\n David Aguilar, PhD, Chief Operating Officer, expressed his enthusiasm for the collaboration: \"This partnership represents a pivotal moment in the pursuit of advanced genome editing technologies. By integrating our ABBIE system with microfluidic gene editing capabilities, we can accelerate research and bring innovative, cost-efficient micro-dosed CAR-T treatments to the clinic. Most importantly, our efforts will provide new hope for patients battling cancer.\"\r\n The proposed project aims to streamline gene editing and CAR-T cell processes, making them more accessible and effective for therapeut...